دورية أكاديمية
Clinically low-risk prostate cancer: evaluation with transrectal doppler ultrasound and functional magnetic resonance imaging.
| العنوان: | Clinically low-risk prostate cancer: evaluation with transrectal doppler ultrasound and functional magnetic resonance imaging. |
|---|---|
| المؤلفون: | Novis MI; Faculdade de Medicina da Universidade de São Paulo--Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil., Baroni RH, Cerri LM, Mattedi RL, Buchpiguel CA |
| المصدر: | Clinics (Sao Paulo, Brazil) [Clinics (Sao Paulo)] 2011; Vol. 66 (1), pp. 27-34. |
| نوع المنشور: | Evaluation Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101244734 Publication Model: Print Cited Medium: Internet ISSN: 1980-5322 (Electronic) Linking ISSN: 18075932 NLM ISO Abbreviation: Clinics (Sao Paulo) Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2022- : [New York] : Elsevier Original Publication: São Paulo, SP : Hospital das Clínicas, Faculty of Medicine, University of São Paulo, [2005]- |
| مواضيع طبية MeSH: | Neoplasm Staging/*methods , Prostatic Neoplasms/*diagnostic imaging , Prostatic Neoplasms/*pathology, Aged ; Biopsy ; Contrast Media ; Humans ; Magnetic Resonance Imaging ; Magnetic Resonance Spectroscopy ; Male ; Middle Aged ; Predictive Value of Tests ; Prostate-Specific Antigen/analysis ; Prostatectomy ; Risk Factors ; Ultrasonography, Doppler/methods |
| مستخلص: | Objectives: To evaluate transrectal ultrasound, amplitude Doppler ultrasound, conventional T2-weighted magnetic resonance imaging, spectroscopy and dynamic contrast-enhanced magnetic resonance imaging in localizing and locally staging low-risk prostate cancer. Introduction: Prostate cancer has been diagnosed at earlier stages and the most accepted classification for low-risk prostate cancer is based on clinical stage T1c or T2a, Gleason score ≤6, and prostate-specific antigen (PSA) ≤10 ng/ml. Methods: From 2005 to 2006, magnetic resonance imaging was performed in 42 patients, and transrectal ultrasound in 26 of these patients. Seven patients were excluded from the study. Mean patient age was 64.94 years and mean serum PSA was 6.05 ng/ml. The examinations were analyzed for tumor identification and location in prostate sextants, detection of extracapsular extension, and seminal vesicle invasion, using surgical pathology findings as the gold standard. Results: Sixteen patients (45.7%) had pathologically proven organ-confined disease, 11 (31.4%) had positive surgical margin, 8 (28.9%) had extracapsular extension, and 3 (8.6%) presented with extracapsular extension and seminal vesicle invasion. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy values for localizing low-risk prostate cancer were 53.1%, 48.3%, 63.4%, 37.8% and 51.3% for transrectal ultrasound; 70.4%, 36.2%, 65.1%, 42.0% and 57.7% for amplitude Doppler ultrasound; 71.5%, 58.9%, 76.6%, 52.4% and 67.1% for magnetic resonance imaging; 70.4%, 58.7%, 78.4%, 48.2% and 66.7% for magnetic resonance spectroscopy; 67.2%, 65.7%, 79.3%, 50.6% and 66.7% for dynamic contrast-enhanced magnetic resonance imaging, respectively. Sensitivity, specificity, PPV, NPV and accuracy values for detecting extracapsular extension were 33.3%, 92%, 14.3%, 97.2% and 89.7% for transrectal ultrasound and 50.0%, 77.6%, 13.7%, 95.6% and 75.7% for magnetic resonance imaging, respectively. For detecting seminal vesicle invasion, these values were 66.7%, 85.7%, 22.2%, 97.7% and 84.6% for transrectal ultrasound and 40.0%, 83.1%, 15.4%, 94.7% and 80.0% for magnetic resonance imaging. Conclusion: Although preliminary, our results suggest that imaging modalities have limited usefulness in localizing and locally staging clinically low-risk prostate cancer. |
| References: | Curr Opin Urol. 2008 Jan;18(1):78-86. (PMID: 18090495) J Clin Oncol. 2004 Jun 1;22(11):2141-9. (PMID: 15169800) Int J Urol. 2002 May;9(5):257-60. (PMID: 12060438) Eur Radiol. 2002 Sep;12(9):2294-302. (PMID: 12195484) Radiology. 2006 Mar;238(3):929-37. (PMID: 16424250) Eur Urol. 2000 Jun;37(6):670-4. (PMID: 10828666) JAMA. 1998 Sep 16;280(11):969-74. (PMID: 9749478) Radiology. 2007 Oct;245(1):176-85. (PMID: 17717328) Eur Urol. 2006 Dec;50(6):1163-74; discussion 1175. (PMID: 16842903) BJU Int. 2009 Jun;103(12):1647-54. (PMID: 19154461) Urology. 2008 Dec;72(6 Suppl):S12-24. (PMID: 19095124) Radiology. 2006 Feb;238(2):597-603. (PMID: 16344335) Cancer. 2008 Mar 1;112(5):971-81. (PMID: 18186496) Radiology. 2008 Jan;246(1):177-84. (PMID: 18024434) Lancet. 2008 May 17;371(9625):1710-21. (PMID: 18486743) Radiology. 2009 Apr;251(1):122-33. (PMID: 19332850) World J Urol. 2008 Oct;26(5):415-22. (PMID: 18568350) Radiology. 2004 Jul;232(1):133-9. (PMID: 15166321) J Urol. 2007 Jan;177(1):107-12; discussion 112. (PMID: 17162015) J Urol. 1997 Feb;157(2):559-62. (PMID: 8996356) Nat Rev Urol. 2010 Mar;7(3):136-42. (PMID: 20157302) Curr Opin Urol. 2009 Mar;19(2):168-76. (PMID: 19188771) Radiology. 1997 Mar;202(3):697-702. (PMID: 9051019) Radiology. 2004 Dec;233(3):701-8. (PMID: 15564406) Br J Radiol. 2009 Feb;82(974):148-56. (PMID: 19168692) Eur Urol. 1998;33(3):261-70. (PMID: 9555550) |
| المشرفين على المادة: | 0 (Contrast Media) EC 3.4.21.77 (Prostate-Specific Antigen) |
| تواريخ الأحداث: | Date Created: 20110326 Date Completed: 20111102 Latest Revision: 20220629 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC3044567 |
| DOI: | 10.1590/s1807-59322011000100006 |
| PMID: | 21437432 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1980-5322 |
|---|---|
| DOI: | 10.1590/s1807-59322011000100006 |